Drug Profile


Alternative Names: CP-101,606; Nectiv

Latest Information Update: 17 Apr 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Antiparkinsonians; Neuroprotectants
  • Mechanism of Action NR2B N-Methyl-D-Aspartate antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued CNS trauma; Major depressive disorder; Parkinson's disease; Stroke

Most Recent Events

  • 31 Dec 2010 Discontinued - Phase-II for Major depressive disorder in USA (IV)
  • 31 Dec 2010 Discontinued - Phase-II for Parkinson's disease in USA (IV)
  • 31 Dec 2010 Discontinued - Phase-II for Stroke in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top